sFLC ratio abnormality in relation with different biologic and clinical markers in CLL patients
| . | sFLC . | |||
|---|---|---|---|---|
| All patients, no. (%) . | Normal, no. (%) . | Abnormal, no. (%) . | P . | |
| CD38 | 410 (100) | 270 (65.9) | 140 (34.1) | |
| Negative | 330 (80.5) | 234 (70.9) | 96 (29.1) | < .0001* |
| Positive | 80 (19.5) | 36 (45.0) | 44 (55.0) | |
| ZAP-70 | 401 (100) | 267 (66.6) | 134 (33.4) | |
| Negative | 261 (65.1) | 191 (73.2) | 70 (26.8) | < .0001† |
| Positive | 140 (34.9) | 76 (54.3) | 64 (45.7) | |
| IGHV status | 379 (100) | 257 (67.8) | 122 (32.2) | |
| Mutated | 249 (65.7) | 182 (73.1) | 67 (26.9) | .003* |
| Unmutated | 130 (34.3) | 75 (57.7) | 55 (42.3) | |
| Binet stage | 449 (100) | 299 (66.6) | 150 (33.4) | |
| A | 331 (80.5) | 232 (70.1) | 99 (29.9) | .012* |
| B + C | 118 (19.5) | 67 (56.8) | 51 (43.2) | |
| FISH | 303 (100) | 205 (67.7) | 98 (32.3) | |
| 13q14.3 and normal (low risk) | 208 (71.9) | 154 (70.6) | 64 (29.4) | |
| Trisomy 12 (intermediate risk) | 32 (10.6) | 19 (59.4) | 13 (40.6) | .20† |
| 11q22.3 and 17p13.1 (high risk) | 53 (17.5) | 32 (60.4) | 21 (39.6) | |
| . | sFLC . | |||
|---|---|---|---|---|
| All patients, no. (%) . | Normal, no. (%) . | Abnormal, no. (%) . | P . | |
| CD38 | 410 (100) | 270 (65.9) | 140 (34.1) | |
| Negative | 330 (80.5) | 234 (70.9) | 96 (29.1) | < .0001* |
| Positive | 80 (19.5) | 36 (45.0) | 44 (55.0) | |
| ZAP-70 | 401 (100) | 267 (66.6) | 134 (33.4) | |
| Negative | 261 (65.1) | 191 (73.2) | 70 (26.8) | < .0001† |
| Positive | 140 (34.9) | 76 (54.3) | 64 (45.7) | |
| IGHV status | 379 (100) | 257 (67.8) | 122 (32.2) | |
| Mutated | 249 (65.7) | 182 (73.1) | 67 (26.9) | .003* |
| Unmutated | 130 (34.3) | 75 (57.7) | 55 (42.3) | |
| Binet stage | 449 (100) | 299 (66.6) | 150 (33.4) | |
| A | 331 (80.5) | 232 (70.1) | 99 (29.9) | .012* |
| B + C | 118 (19.5) | 67 (56.8) | 51 (43.2) | |
| FISH | 303 (100) | 205 (67.7) | 98 (32.3) | |
| 13q14.3 and normal (low risk) | 208 (71.9) | 154 (70.6) | 64 (29.4) | |
| Trisomy 12 (intermediate risk) | 32 (10.6) | 19 (59.4) | 13 (40.6) | .20† |
| 11q22.3 and 17p13.1 (high risk) | 53 (17.5) | 32 (60.4) | 21 (39.6) | |